A California company, Okava Pharmaceuticals, has initiated a clinical trial to evaluate a GLP-1-based weight loss treatment for overweight cats. The trial, known as MEOW-1, involves 50 cats and tests an under-the-skin implant, called OKV-119, which is designed to release medication gradually over a six-month period.
Read More
The treatment aims to replicate many physiological effects of fasting, such as enhanced insulin sensitivity and efficient energy metabolism, without requiring major changes in feeding habits that could disrupt the bond between pets and their owners. The company believes this approach could improve cats’ quality of life and support healthy aging.
Currently, approximately 60% of cats in the United States are considered overweight, which poses a higher risk for conditions like diabetes and other health issues. According to Dr. Ernie Ward, a veterinarian and expert on pet obesity, traditional advice in veterinary medicine has been limited to reducing food intake and increasing exercise, which may not be effective for all obesity types.
Dr. Ward noted that human studies suggest potential benefits of the new treatment extend beyond weight loss to include improvements in diabetes management and overall health. Uncertainties remain regarding the cost of the implant, potential side effects, and its effectiveness in practice. Okava estimates the monthly expense for pet owners could be around $100 if the implant receives approval.
Some pet owners, like Savannah Tielking, whose cat weighs 21 pounds, are open to considering the treatment if recommended by veterinarians. She expressed concern about her cat's health, stating she would seriously consider the implant if it could address diabetes after other options have failed.
Results from the MEOW-1 study are expected by next summer, and Okava intends to pursue FDA approval for the implant within the next two years. The company is also developing a similar version of the implant for dogs.